Second-Generation Hydrogel Coils for the Endovascular Treatment of Intracranial Aneurysms: A Randomized Controlled Trial
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Second-Generation Hydrogel Coils for the Endovascular Treatment of Intracranial Aneurysms: A Randomized Controlled Trial |
Type de publication | Journal Article |
Year of Publication | 2018 |
Auteurs | Taschner CA, Chapot R, Costalat V, Machi P, Courtheoux P, Barreau X, Berge J, Pierot L, Kadziolka K, Jean B, Blanc R, Biondi A, Brunel H, Gallas S, Berlis A, Herbreteau D, Berkefeld J, Urbach H, Elsheikh S, Fiehler J, Desal H, Graf E, Bonafe A |
Journal | STROKE |
Volume | 49 |
Pagination | 667-674 |
Date Published | MAR |
Type of Article | Article |
ISSN | 0039-2499 |
Mots-clés | aneurysm, embolization, Hydrogel, intracranial aneurysm, polyethylene glycol dimethacrylate, Randomized controlled trial, ruptured, therapeutic |
Résumé | {Background and Purpose Endovascular embolization of intracranial aneurysms with hydrogel-coated coils lowers the risk of major recurrence, but technical limitations (coil stiffness and time restriction for placement) have prevented their wider clinical use. We aimed to assess the efficacy of softer, second-generation hydrogel coils. Methods A randomized controlled trial was conducted at 22 centers in France and Germany. Patients aged 18 to 75 years with untreated ruptured or unruptured intracranial aneurysms measuring 4 to 12 mm in diameter were eligible and randomized (1:1 using a web-based system, stratified by rupture status) to coiling with either second-generation hydrogel coils or bare platinum coils. Assist devices were allowed as clinically required. Independent imaging core laboratory was masked to allocation. Primary end point was a composite outcome measure including major aneurysm recurrence, aneurysm retreatment, morbidity that prevented angiographic controls, and any death during treatment and follow-up. Data were analyzed as randomized. Results Randomization began on October 15, 2009, and stopped on January 31, 2014, after 513 patients (hydrogel |
DOI | 10.1161/STROKEAHA.117.018707 |